Table 5

Univariate and multivariable analyses of brain PFS and OS in patients with brain metastasis at baseline (N = 53)
Risk Factor Univariate analysis Multivariable analysisa
Brain PFS OS Brain PFS OS
HR 95 % CI P HR 95 % CI P HR 95 % CI P HR 95 % CI P
Prior capecitabine vs. no prior capecitabine 1.20 0.68-2.11 0.5377 1.22 0.67-2.22 0.5195
Hormone receptor positive vs. hormone receptor negative 0.56 0.31 -1.00 0.0507 0.62 0.34-1.13 0.1190 0.38 0.20-0.72 0.0031
Best systemic response SD < 6 m, PD vs. CR, PR, SD ≥ 6 m 2.47 1.39-4.40 0.0022 3.55 1.89-6.67 <0.0001
Median trastuzumab duration, wks ≥35.4 vs. <35.4 0.85 0.48-1.50 0.5672 0.45 0.24-0.85 0.0140 0.50 0.25-0.99 0.0476
Age at ≥50 vs. <50 0.67 0.36-1.23 0.1925 1.13 0.61-2.13 0.6958
No. of metastasis ≥3 vs. <3 0.81 0.44-1.48 0.4918 1.10 0.57-2.13 0.7733
No. of prior chemotherapy regimens >3 vs. ≤ 3 0.88 0.48-1.61 0.6835 1.48 0.79-2.76 0.2169
Pattern of metastasis Visceral only vs other 1.51 0.80-2.85 0.1994 1.16 0.58-2.31 0.6778
Median TTbrainP, wks ≥30.7 vs. <30.7 0.44 0.24-0.82 0.0095 0.58 0.29-1.16 0.1223
Median interval from brain metastasis diagnosis to study enrollment, wks ≥8.1 vs. <8.1 1.42 0.80-2.53 0.2365 1.49 0.81-2.74 0.2032
Brain response* SD < 6 m, PD vs. CR, PR, any response, SD ≥ 6 m 7.44 3.42-16.18 <0.0001 1.79 0.85-3.77 0.1263
Brain response & systemic response Else vs . Both of CR, PR, SD ≥ 6 m 2.82 1.57-5.09 0.0006 3.16 1.68-5.96 0.0004 3.65 1.95-6.85 <0.0001 2.18 1.07-4.42 0.0311

a Risk factors were determined using univariate Cox’s proportional hazards regression (α <0.10).

* excluded 2patients with not evaluable reponse.

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; TTbrainP, time to brain progression.

HR, hazard ratio; CI, confidence interval.

Ro et al.

Ro et al. BMC Cancer 2012 12:322   doi:10.1186/1471-2407-12-322

Open Data